Takeda/Nycomed

Takeda wins auction for Nycomed

Takeda agrees to pay $14 billion for Swiss drug company Nycomed in Japan's largest-ever pharma M&A deal.

Takeda Pharmaceutical is set to buy Nycomed for 9.6 billion $13.7 billion in cash, in Japan’s second-largest outbound MA deal and its largest healthcare MA deal.

Takeda is already Japan’s largest pharmaceutical company and the acquisition will consolidate its position by some margin. But, equally, the deal will add to Takeda’s drug pipeline and its geographical reach.

Nycomed is well established in Europe and some high-growth emerging markets, with the majority of its revenues from prescription pharmaceutical products and a smaller presence in over-the-counter products. This complements Takeda’s presence in the Japanese and US markets and immediately doubles Takeda’s European sales. Nycomed’s more than 2.8...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222